UY33807A - miRNAs as indicators of tissue status or of diseases such as osteoarthritis - Google Patents

miRNAs as indicators of tissue status or of diseases such as osteoarthritis

Info

Publication number
UY33807A
UY33807A UY0001033807A UY33807A UY33807A UY 33807 A UY33807 A UY 33807A UY 0001033807 A UY0001033807 A UY 0001033807A UY 33807 A UY33807 A UY 33807A UY 33807 A UY33807 A UY 33807A
Authority
UY
Uruguay
Prior art keywords
osteoarthritis
mirnas
indicators
diseases
tissue status
Prior art date
Application number
UY0001033807A
Other languages
Spanish (es)
Inventor
Dr Kathrin Heermeier
Dr Thomas Leeuw
Dl Christiane Metz-Weidmann
Dr Joachim Saas
Dr Jochen Beninga
Dr Uwe Dietz
Dr Tilo Weiss
Dr Eckart Bartnik
Dr Hans Schneider
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33807A publication Critical patent/UY33807A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

La presente invención se refiere a microRNA (miRNA), en particular mir-22, como indicador de un estado del tejido o una enfermedad tal como artrosis (OA) y como molécula diana para el descubrimiento de una sustancia para el tratamiento de una artropatía. También se proveen métodos y compuestos para investigación, análisis y/o tratamiento de una artropatía, especialmente OA.The present invention relates to microRNA (miRNA), in particular mir-22, as an indicator of a state of tissue or a disease such as osteoarthritis (OA) and as a target molecule for the discovery of a substance for the treatment of arthropathy. Methods and compounds are also provided for research, analysis and / or treatment of an arthropathy, especially OA.

UY0001033807A 2010-12-17 2011-12-15 miRNAs as indicators of tissue status or of diseases such as osteoarthritis UY33807A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306443 2010-12-17

Publications (1)

Publication Number Publication Date
UY33807A true UY33807A (en) 2012-07-31

Family

ID=45560875

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033807A UY33807A (en) 2010-12-17 2011-12-15 miRNAs as indicators of tissue status or of diseases such as osteoarthritis

Country Status (4)

Country Link
AR (1) AR084332A1 (en)
TW (1) TW201238973A (en)
UY (1) UY33807A (en)
WO (1) WO2012080459A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127736A1 (en) * 2016-04-29 2019-05-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN111918968B (en) 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Inhibitors of Micro-RNA 22
WO2019229489A1 (en) * 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mir-146a-5p and mir-186 as biomarkers of osteoarthritis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methods for the production of humanized antibodies
AU8088694A (en) 1993-10-27 1995-05-22 Ribozyme Pharmaceuticals, Inc. 2'-amido and 2'-peptido modified oligonucleotides
FR2739031B1 (en) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique TRANSDERMAL MATRIX SYSTEM FOR ADMINISTRATION OF AN ESTROGEN AND / OR A PROGESTIVE BASED ON STYRENE-ISOPRENE-STYRENE COPOLYMER, PREPARATION METHOD AND THERAPEUTIC USE
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
DK0889723T3 (en) 1996-03-25 2002-09-23 Lohmann Therapie Syst Lts Transdermal therapeutic system with low thickness of administration area and great flexibility and method of preparation thereof
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
JP2001524942A (en) 1997-02-24 2001-12-04 ティーエム テクノロジーズ，インク． Antisense oligonucleotide drugs
US8288358B2 (en) * 2007-03-26 2012-10-16 Newcastle Innovation Ltd. Therapeutic targets and molecules
WO2008142567A2 (en) * 2007-05-18 2008-11-27 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells

Also Published As

Publication number Publication date
AR084332A1 (en) 2013-05-08
WO2012080459A1 (en) 2012-06-21
TW201238973A (en) 2012-10-01

Similar Documents

Publication Publication Date Title
ECSP13012572A (en) ANALOGS OF NUCLEOTID REPLACED
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
GT201400063A (en) BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
CR20120529A (en) DERIVATIVES OF THE ACID 1-AMINO-2-CICLOPROPILETILBORONICO
EA201890915A1 (en) CONJUGATES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DISEASES CAUSED BY CELLS EXPRESSING PSMA
CU20140048A7 (en) NEW PURINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS
CO6670585A2 (en) Promoters of apotosis n-acilsufonamides
CO7240369A2 (en) Novel 5-aminotetrahydroquinolin-2-carboxylic acid and its use
CO6751275A2 (en) Triterpenoids c-17 and c-3 modified with the maturation inhibitory activity of human immunodeficiency virus
UY33776A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE
CO6511283A2 (en) USEFUL REPLACED PRIMIDINES IN THE TREATMENT OF DISEASES SUCH AS CANCER
CY1120204T1 (en) AMORPHIC SOLID SOLAR DISPOSAL FOR USE IN BRAND CANCER TREATMENT
EA201070421A1 (en) MICRORIPONIC ACID
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
BR112015014987A2 (en) IMPROVED EXON-SKIPPING COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
EA201500426A1 (en) PYRROLOTRIAZINON DERIVATIVES AS PI3K INHIBITORS
CO6990719A2 (en) Derivatives of the nucleosides substituted in 4'-azido, 3'-fluoro as inhibitors of the replication of the vna rna
ECSP13012448A (en) NEW AMINOPIRAZOLOQUINAZOLINAS.
EA201491028A1 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
EA201400976A1 (en) BENZODIOXANES IN COMBINATION WITH OTHER ACTIVE MEANS TO INHIBIT LEUKOTRIEN PRODUCTION
EA201490643A1 (en) NEW BETULINIC ACID DERIVATIVES WITH ANTI-VIRUS ACTIVITY
ECSP11010816A (en) New Compounds
ECSP13012613A (en) METHOD FOR PRODUCING AND USING A SOUND CARBOXIMETILCELLULOSE AND GOSIPOL COPOLYMER
UY33807A (en) miRNAs as indicators of tissue status or of diseases such as osteoarthritis
AR084331A1 (en) microRNA (miRNA) IN ARTICULAR DISEASES